Alameda, California
United States
65
2026-06-04
55
2025-04-15
These are the the leading inventors for applications assigned to Exelixis, Inc.:
Exelixis, Inc. based in Alameda, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
#2 | 2025-10-235T4 BINDING AGENTS AND USES THEREOF
#3 | 2025-09-255T4 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#4 | 2025-06-19MULTISPECIFIC BINDING AGENTS AND USES THEREOF
#5 | 2025-03-27PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES
#6 | 2025-03-13 β Patent 12,275,706 granted on 2025-04-15Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-Nβ²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#7 | 2024-11-28ANTI-ROR ANTIBODY CONSTRUCTS
#8 | 2024-06-13 β Patent 12,128,039 granted on 2024-10-29Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
#9 | 2024-01-11MULTISPECIFIC BINDING AGENTS AND USES THEREOF
#10 | 2024-01-11 β Patent 12,227,481 granted on 2025-02-18Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
#11 | 2023-11-30 β Patent 12,264,161 granted on 2025-04-01Heterocyclic adenosine receptor antagonists
#12 | 2023-11-30 β Patent 12,486,233 granted on 2025-12-02CRYSTALLINE SOLID FORMS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE
#13 | 2023-11-23 β Patent 12,195,475 granted on 2025-01-14Compounds for the treatment of kinase-dependent disorders
#14 | 2023-11-09CD47 BINDING AGENTS AND USES THEREOF
#15 | 2023-09-28PD-L1 BINDING AGENTS AND USES THEREOF
#16 | 2023-09-28 β Patent 11,969,419 granted on 2024-04-30Method of treating cancer
#17 | 2023-09-28 β Patent 12,016,854 granted on 2024-06-25Liquid dosage forms to treat cancer
#18 | 2023-06-22 β Patent 12,497,367 granted on 2025-12-16Processes for the Preparation of a Kinase Inhibitor
#19 | 2023-02-09 β Patent 12,503,438 granted on 2025-12-23Compounds for the Treatment of Kinase-Dependent Disorders
#20 | 2023-01-26 β Patent 12,017,995 granted on 2024-06-25Crystalline forms and salt forms of a kinase inhibitor
#21 | 2022-10-06 β Patent 12,371,428 granted on 2025-07-29PYRIDONE COMPOUNDS AND METHODS OF USE
#22 | 2021-09-23 β Patent 11,718,622 granted on 2023-08-08Heterocyclic adenosine receptor antagonists
#23 | 2021-08-26 β Patent 11,279,675 granted on 2022-03-22Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-Nβ²-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
#24 | 2021-08-19 β Patent 11,124,482 granted on 2021-09-21C-met modulators and methods of use
#25 | 2021-07-08 β Patent 11,760,726 granted on 2023-09-19Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
#26 | 2021-06-03 β Patent 11,098,015 granted on 2021-08-24Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-Nβ²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#27 | 2021-06-03 β Patent 11,298,349 granted on 2022-04-12Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
#28 | 2021-05-27 β Patent 12,084,496 granted on 2024-09-10Anti-ROR antibody constructs
#29 | 2021-05-13 β Patent 11,091,440 granted on 2021-08-17Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- Nβ²-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
#30 | 2021-02-11 β Patent 11,708,367 granted on 2023-07-25Compounds for the treatment of kinase-dependent disorders
#31 | 2021-02-11 β Patent 11,542,259 granted on 2023-01-03Compounds for the treatment of kinase-dependent disorders
#32 | 2021-02-04 β Patent 11,673,897 granted on 2023-06-13Compounds for the treatment of kinase-dependent disorders
#33 | 2021-02-04Triple Negative Breast Cancer Treatment Method
#34 | 2021-01-28 β Patent 11,091,439 granted on 2021-08-17Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-Nβ²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
#35 | 2020-12-17 β Patent 11,414,396 granted on 2022-08-16Process for making compounds for use in the treatment of cancer
#36 | 2020-10-22 β Patent 11,433,064 granted on 2022-09-06Methods of using c-Met modulators
#37 | 2020-10-22 β Patent 11,612,597 granted on 2023-03-28Method of treating cancer
#38 | 2020-09-10 β Patent 11,597,699 granted on 2023-03-07MEK inhibitors and methods of their use
#39 | 2020-08-27 β Patent 11,504,362 granted on 2022-11-22Liquid dosage forms to treat cancer
#40 | 2020-08-13 β Patent 11,254,649 granted on 2022-02-22Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
#41 | 2020-08-13 β Patent 11,504,363 granted on 2022-11-22Method of treating cancer and bone cancer pain
#42 | 2020-06-18 β Patent 10,851,061 granted on 2020-12-01Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-Nβ²-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
#43 | 2020-04-23 β Patent 11,123,338 granted on 2021-09-21C-met modulator pharmaceutical compositions
#44 | 2019-11-21 β Patent 11,198,731 granted on 2021-12-14Combinations of cabozantinib and atezolizumab to treat cancer
#45 | 2019-07-11 β Patent 11,141,413 granted on 2021-10-12Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-Nβ²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
#46 | 2019-06-20 β Patent 10,793,541 granted on 2020-10-06Process for making compounds for use in the treatment of cancer
#47 | 2019-05-23 β Patent 10,736,886 granted on 2020-08-11Methods of using c-Met modulators
#48 | 2019-03-28 β Patent 11,116,759 granted on 2021-09-14Method of treating cancer
#49 | 2019-01-31 β Patent 10,543,206 granted on 2020-01-28Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
#50 | 2018-12-06 β Patent 10,590,102 granted on 2020-03-17Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
#51 | 2017-12-14 β Patent 11,124,482 granted on 2021-09-21C-met modulators and methods of use
#52 | 2017-12-07 β Patent 10,239,858 granted on 2019-03-26Process for making compounds for use in the treatment of cancer
#53 | 2017-10-19 β Patent 10,328,069 granted on 2019-06-25Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
#54 | 2017-09-21 β Patent 10,034,873 granted on 2018-07-31C-met modulator pharmaceutical compositions
#55 | 2017-08-10 β Patent 10,053,470 granted on 2018-08-21Inhibitors of PI3K-delta and methods of their use and manufacture
#56 | 2017-08-10 β Patent 11,065,240 granted on 2021-07-20Drug combinations to treat multiple myeloma
#57 | 2017-08-03 β Patent 11,124,481 granted on 2021-09-21Method of preparing fluorine-18 labeled Cabozantinib and its analogs
#58 | 2017-05-25 β Patent 10,039,757 granted on 2018-08-07C-Met modulator pharmaceutical compositions
#59 | 2017-03-30 β Patent 10,159,666 granted on 2018-12-25Dosing of cabozantinib formulations
#60 | 2017-03-02 β Patent 10,123,999 granted on 2018-11-13Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
#61 | 2017-02-16 β Patent 10,501,418 granted on 2019-12-10Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-Nβ²-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
#62 | 2016-02-04 β Patent 10,273,211 granted on 2019-04-30Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-Nβ²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
#63 | 2016-01-28 β Patent 11,564,915 granted on 2023-01-31Cabozantinib dosage form and use in the treatment of cancer
#64 | 2015-09-24 β Patent 10,035,790 granted on 2018-07-31RORΞ³ modulators
#65 | 2014-08-14 β Patent 10,166,225 granted on 2019-01-01Method for treating osteoporosis
Also check out Exelixis, Inc.'s (Alameda, United States) applicant profile with 74 patent applications submitted.
307005 β